TY - JOUR
T1 - Importance of dose intensity in neuro-oncology clinical trials
T2 - Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
AU - Doolittle, Nancy D.
AU - Anderson, Clarke P.
AU - Bleyer, W. Archie
AU - Cairncross, J. Gregory
AU - Cloughesy, Timothy
AU - Eck, Stephen L.
AU - Guastadisegni, Paul
AU - Hall, Walter A.
AU - Muldoon, Leslie L.
AU - Patel, Sunil J.
AU - Peereboom, David
AU - Siegal, Tali
AU - Neuwelt, Edward A.
PY - 2001/1
Y1 - 2001/1
N2 - Therapeutic options for the treatment of malignant brain tumors have been limited, in part, because of the presence of the blood-brain barrier. For this reason, the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium, the focus of which was the "Importance of Dose Intensity in Neuro-Oncology Clinical Trials," was convened in April 2000, at Government Camp, Mount Hood, Oregon. This meeting, which was supported by the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the National Institute of Deafness and Other Communication Disorders, brought together clinicians and basic scientists from across the U.S. to discuss the role of dose intensity and enhanced chemotherapy delivery in the treatment of malignant brain tumors and to design multicenter clinical trials. Optimizing chemotherapy delivery to the CNS is crucial, particularly in view of recent progress identifying certain brain tumors as chemosensitive. The discovery that specific constellations of genetic alterations can predict which tumors are chemoresponsive, and can therefore more accurately predict prognosis, has important implications for delivery of intensive, effective chemotherapy regimens with acceptable toxicities. This report summarizes the discussions, future directions, and key questions regarding dose-intensive treatment of primary CNS lymphoma, CNS relapse of systemic non-Hodgkin's lymphoma, anaplastic oligodendroglioma, high-grade glioma, and metastatic cancer of the brain. The promising role of cytoenhancers and chemoprotectants as part of dose-intensive regimens for chemosensitive brain tumors and development of improved gene therapies for malignant gliomas are discussed.
AB - Therapeutic options for the treatment of malignant brain tumors have been limited, in part, because of the presence of the blood-brain barrier. For this reason, the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium, the focus of which was the "Importance of Dose Intensity in Neuro-Oncology Clinical Trials," was convened in April 2000, at Government Camp, Mount Hood, Oregon. This meeting, which was supported by the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the National Institute of Deafness and Other Communication Disorders, brought together clinicians and basic scientists from across the U.S. to discuss the role of dose intensity and enhanced chemotherapy delivery in the treatment of malignant brain tumors and to design multicenter clinical trials. Optimizing chemotherapy delivery to the CNS is crucial, particularly in view of recent progress identifying certain brain tumors as chemosensitive. The discovery that specific constellations of genetic alterations can predict which tumors are chemoresponsive, and can therefore more accurately predict prognosis, has important implications for delivery of intensive, effective chemotherapy regimens with acceptable toxicities. This report summarizes the discussions, future directions, and key questions regarding dose-intensive treatment of primary CNS lymphoma, CNS relapse of systemic non-Hodgkin's lymphoma, anaplastic oligodendroglioma, high-grade glioma, and metastatic cancer of the brain. The promising role of cytoenhancers and chemoprotectants as part of dose-intensive regimens for chemosensitive brain tumors and development of improved gene therapies for malignant gliomas are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0035222363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035222363&partnerID=8YFLogxK
U2 - 10.1093/neuonc/3.1.46
DO - 10.1093/neuonc/3.1.46
M3 - Article
C2 - 11305417
AN - SCOPUS:0035222363
VL - 3
SP - 46
EP - 54
JO - Neuro-Oncology
JF - Neuro-Oncology
SN - 1522-8517
IS - 1
ER -